Related Experiment Video

Updated: Jun 5, 2026

Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging
09:43

Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging

Published on: January 10, 2025

Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular

Emilie Dubois1, Marie Fertin, Justine Burdese

  • 1INSERM, Lille, France.

Proteomics. Clinical Applications
|January 20, 2011
PubMed

Insights

Identifying novel heart failure (HF) biomarkers through proteomics is crucial. Proteomic analysis of blood samples aids in discovering new HF biomarkers for personalized medicine, though standardization and validation remain challenges.

Area of Science:

  • Biochemistry
  • Cardiology
  • Proteomics

Background:

  • Heart failure (HF) is a serious condition with a poor prognosis.
  • Biomarkers for HF are essential for diagnosis, risk stratification, and therapy selection.
  • Circulating analytes in serum or plasma are commonly referred to as HF biomarkers.

Purpose of the Study:

  • To explore the role of proteomics in discovering novel heart failure biomarkers.
  • To highlight the clinical applications of HF biomarkers.
  • To address challenges in biomarker discovery using proteomic approaches.

Main Methods:

  • Proteomic studies utilizing case/control designs with clinical or surrogate endpoints.
  • Analysis of various sample types, with a focus on easily accessible serum and plasma.
  • Investigating methods to overcome challenges in accessing low-abundance proteins.

Main Results:

  • Proteomics plays a significant role in the discovery phase of HF biomarkers.
  • Plasma and serum samples are frequently used due to accessibility.
  • Standardization of sampling and detection of low-abundance proteins are key challenges.

Conclusions:

  • Proteomic research holds promise for identifying new circulating HF biomarkers.
  • Validation of discovered biomarkers using specific methods in independent populations is necessary.
  • Advancements in HF biomarker discovery can lead to more personalized medicine approaches.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...